Health Care • Biotechnology: Pharmaceutical Preparations
$54.54 ▲ +0.38
(+0.70%)
MKT CAP: $2.63B • VOL: 257.2K
52W L $20 52W H $73
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
MBX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$98.1M | -$68.2M | -$35.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$87.0M | -$61.9M | -$32.6M |
| EBITDA (Normalized) | -$96.5M | -$67.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$79.9M | -$54.7M | -$32.0M |
| Capital Expenditures (CapEx) | $1.9M | $874.0K | — |
| Free Cash Flow (FCF) | -$81.9M | -$55.6M | -$32.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -26.4% | -25.9% | — |
| Cash & Short-Term Equivalents | $75.3M | $49.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $369.2M | $257.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MBX.